Eventide Asset Management LLC Has $14.56 Million Stock Holdings in United Therapeutics Corporation $UTHR

Key Points

• Eventide Asset Management LLC reduced its stake in United Therapeutics Corporation by 30.3%, selling 20,584 shares and now owning 47,241 shares valued at approximately $14.56 million.
• United Therapeutics reported EPS of $6.41 for the last quarter, which was below the consensus estimate of $6.80, amid a revenue of $798.6 million, slightly short of expectations.
• The stock is currently facing downward pressure, with shares down 3.3% and an average price target of approximately $423.85, suggesting potential upside for investors.

Eventide Asset Management LLC reduced its stake in United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 30.3% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 47,241 shares of the biotechnology company's stock after selling 20,584 shares during the period. Eventide Asset Management LLC owned 0.10% of United Therapeutics worth $14,563,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently made changes to their positions in the stock. Hohimer Wealth Management LLC lifted its stake in shares of United Therapeutics by 0.3% in the 1st quarter. Hohimer Wealth Management LLC now owns 12,651 shares of the biotechnology company's stock worth $3,900,000 after acquiring an additional 37 shares during the period. Applied Finance Capital Management LLC lifted its stake in shares of United Therapeutics by 3.7% in the 1st quarter. Applied Finance Capital Management LLC now owns 1,132 shares of the biotechnology company's stock worth $349,000 after acquiring an additional 40 shares during the period. Headlands Technologies LLC lifted its stake in shares of United Therapeutics by 1.5% in the 1st quarter. Headlands Technologies LLC now owns 2,687 shares of the biotechnology company's stock worth $828,000 after acquiring an additional 40 shares during the period. First Financial Bankshares Inc lifted its stake in shares of United Therapeutics by 0.3% in the 1st quarter. First Financial Bankshares Inc now owns 13,769 shares of the biotechnology company's stock worth $4,245,000 after acquiring an additional 42 shares during the period. Finally, Cadence Bank lifted its stake in shares of United Therapeutics by 1.2% in the 1st quarter. Cadence Bank now owns 3,963 shares of the biotechnology company's stock worth $1,222,000 after acquiring an additional 47 shares during the period. 94.08% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on UTHR. Bank of America upped their price target on shares of United Therapeutics from $314.00 to $463.00 and gave the stock a "neutral" rating in a research note on Tuesday. UBS Group increased their target price on shares of United Therapeutics from $415.00 to $560.00 and gave the company a "buy" rating in a research note on Thursday. JPMorgan Chase & Co. cut their target price on shares of United Therapeutics from $350.00 to $330.00 and set an "overweight" rating for the company in a research note on Tuesday, July 8th. Wells Fargo & Company increased their target price on shares of United Therapeutics from $295.00 to $414.00 and gave the company an "equal weight" rating in a research note on Wednesday. Finally, Jefferies Financial Group increased their target price on shares of United Therapeutics from $432.00 to $564.00 and gave the company a "buy" rating in a research note on Tuesday. Nine research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $429.62.

United Therapeutics Stock Performance

Shares of NASDAQ:UTHR traded up $20.05 during mid-day trading on Friday, hitting $400.52. The stock had a trading volume of 924,693 shares, compared to its average volume of 848,265. The company has a market cap of $18.07 billion, a PE ratio of 15.63, a P/E/G ratio of 6.08 and a beta of 0.62. United Therapeutics Corporation has a 12-month low of $266.98 and a 12-month high of $436.95. The company's 50 day moving average is $307.69 and its 200-day moving average is $305.80.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its quarterly earnings results on Wednesday, July 30th. The biotechnology company reported $6.41 EPS for the quarter, missing the consensus estimate of $6.80 by ($0.39). The firm had revenue of $798.60 million during the quarter, compared to analysts' expectations of $802.13 million. United Therapeutics had a net margin of 40.36% and a return on equity of 18.73%. The firm's revenue was up 11.7% compared to the same quarter last year. During the same quarter last year, the company posted $5.85 EPS. On average, equities research analysts predict that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, COO Michael Benkowitz sold 22,500 shares of the company's stock in a transaction that occurred on Tuesday, September 2nd. The shares were sold at an average price of $417.64, for a total value of $9,396,900.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Richard Giltner sold 3,036 shares of the company's stock in a transaction that occurred on Tuesday, June 24th. The shares were sold at an average price of $289.60, for a total transaction of $879,225.60. Following the completion of the sale, the director owned 19,384 shares of the company's stock, valued at approximately $5,613,606.40. This trade represents a 13.54% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 118,181 shares of company stock worth $39,441,679 in the last quarter. Corporate insiders own 10.30% of the company's stock.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.